GlaxoSmithKline has agreed to pay more than $150 million to settle fraud allegations over the pricing and marketing of anti-nausea drugs Zofran and Kytril, the Justice Department said Tuesday. The company admitted no wrongdoing as part of the settlement, which is the latest in a series of actions involving major drug makers that reap millions from Medicare and Medicaid. An assistant AG said last year that the pricing and marketing of 500 drugs made by various manufacturers were under investigation.
September 21, 2005 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
GlaxoSmithKline PLC has agreed to pay more than $150 million to settle fraud allegations over the pricing and marketing of two anti-nausea drugs, the Justice Department said Tuesday.
The pharmaceutical maker engaged in a scheme to inflate the price of Zofran and Kytril for the federal Medicare and Medicaid programs, which reimburse health care providers based on the manufacturers’ prices, the government said. The drugs are used mainly to counter nausea brought on by chemotherapy and radiation.
Presented by BigVoodoo
Join the industry's top owners, investors, developers, brokers and financiers for the real estate healthcare event of the year!
This event shines a spotlight on how individuals and firms are changing the investment advisory industry where it matters most.
This conference aims to help insurers and litigators better manage complex claims and litigation.
Borteck & Czapek, P.C., based in Florham Park, is a boutique estates and trusts law firm specializing in estate planning and administrat...
Gwinnett County State Court is seeking an attorney to assist the Judge by conducting a variety of legal research, analysis, and document pre...
CORE RESPONSIBILITIES AND TASKS:(1) Tasks and responsibilities include:Reviewing and negotiating commercial agreements for internal business...
